AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00006330
Drug: Hawthorn
RxNorm normalized name: hawthorn
DrugBank: Hawthorn leaf with flower (DB15839)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000924
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000924
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000924
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000924
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000924
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05519202
Drug: S-1,Oxaliplatin, Penpulimab
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
Trial: NCT06137105
Drug: eltrombopag and romiplastim
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group I: eltrombopag and romiplastim~Group II : recived corticosteroid.
Trial: NCT04581733
Drug: MT1621
RxNorm normalized name: MT1621
DrugBank: MT1621 (DB17970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
Trial: NCT04885075
Drug: I/N Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intranasal midazolam 0.2mg/kg/dose stat
Trial: NCT05822934
Drug: Carboplatin-Gemcitabine Cisplatin-Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin-gemcitabine versus cisplatin-gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer
Trial: NCT05445440
Drug: BMS-986371
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05445440
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05752175
Drug: WPV01
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WPV01 tablets
Trial: NCT04718909
Drug: Regorafenib + sintilimab
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w.
Trial: NCT04718909
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg p.o. qd for 3 weeks of every 4 week cycle.
Trial: NCT05801367
Drug: Formocresol
RxNorm normalized name: Formocresol
DrugBank: Cresol (DB11143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
Trial: NCT04695483
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Controlled ovarian stimulation long-acting protocol
Trial: NCT04695483
Drug: Follitropin Beta
RxNorm normalized name: Follitropin Beta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily controlled ovarian stimulation protocol
Trial: NCT05352321
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: for induction chemotherapy
Trial: NCT05352321
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for induction and concurrent chemotherapy
Trial: NCT04583228
Drug: HLX71
RxNorm normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose, intravenous infusion
Trial: NCT05258565
Drug: IV tPA (Activase)
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
Trial: NCT04589832
Drug: PAC-1
RxNorm normalized name: PAC-1
DrugBank: PAC-1 (DB13048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
Trial: NCT04589832
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
Trial: NCT05825365
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib
Trial: NCT00836316
Drug: levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
Trial: NCT04809649
Drug: SUBA-itraconazole
RxNorm normalized name: ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant will receive treatment with SUBA-itraconazole
Trial: NCT06218628
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pacritinib in combination with talazoparib
Trial: NCT06218628
Drug: pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pacritinib in combination with talazoparib
Trial: NCT05260671
Drug: Penpulimab combined with cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 antibody combined with EGFR inhibitors, biweekly
Trial: NCT05342818
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
Trial: NCT05342818
Drug: Ondansetron 8mg
RxNorm normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
Trial: NCT05342818
Drug: Metoclopramide Injection
RxNorm normalized name: metoclopramide Injection
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
Trial: NCT05000216
Drug: Continue IS (MMF or MPA)
RxNorm normalized name: polyurethane-34 (55 MPA)
DrugBank: Urethane (DB04827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
Trial: NCT05000216
Drug: Withhold IS (MMF or MPA)
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
Trial: NCT05000216
Drug: Withhold IS (MTX)
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
Trial: NCT05000216
Drug: Withhold IS (B cell depletion therapy)
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.
Trial: NCT04686929
Drug: Abatacept s.c.
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
Trial: NCT04750291
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 1 infiltration in the biceps muscle with botulinum toxin (100 IU)
Trial: NCT06527898
Drug: hypofractionated radiotherapy with immunotherapy
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hypofractionated radiotherapy with Adebrelimab consolidation
Trial: NCT05474924
Drug: Budesonide intrapolyp injection
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
Trial: NCT05474924
Drug: Budesonide nasal wash
RxNorm normalized name: budesonide Nasal Spray
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
Trial: NCT04687657
Drug: umbilical cord blood
RxNorm normalized name: Autologous umbilical cord blood
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
Trial: NCT05700630
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
Trial: NCT04727840
Drug: Sodium Zirconium Cyclosilicate Oral Product
RxNorm normalized name: sodium zirconium cyclosilicate Oral Product
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly.
Trial: NCT00262496
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT06169202
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2, IV, day 1, repeated every 3 weeks. (Note: If patient has UGT1A1\*28 and \*6 as pure or double heterozygous variants, irinotecan dose 150 mg/m2, IV, day 1, repeated every 3 weeks, with close clinical observation).
Trial: NCT05298020
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg,sc,d1,Q4W
Trial: NCT05809921
Drug: alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.
Trial: NCT05809921
Drug: Alteplase + possible complementary IVT with tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.
Trial: NCT05298020
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 210mg，CIV72h，d1-3，Q4W
Trial: NCT05298020
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125mg/m2,iv,d1,d8,Q4W
Trial: NCT05298020
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, iv,d1,d8，Q4W
Trial: NCT05892614
Drug: efzofitimod 450 mg
RxNorm normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over approximately 60 minutes every 4 weeks
Trial: NCT05282121
Drug: Avenciguat (BI 685509)
RxNorm normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat (BI 685509)
Trial: NCT05282121
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin
Trial: NCT05892614
Drug: efzofitimod 270 mg
RxNorm normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over approximately 60 minutes every 4 weeks
Trial: NCT06107894
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
Trial: NCT05917912
Drug: Amitriptyline Hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
Trial: NCT05906914
Drug: cladribine + homoharringtonine + cytarabine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
Trial: NCT04985929
Drug: Sildenafil 50 mg
RxNorm normalized name: sildenafil 50 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil is a phosphodiesterase type-5 inhibitor, which augments/prolongs the naturally occurring nitric oxide mediated vasodilatory pathway. Sildenafil pill is over-encapsulated to be identical in appearance to the placebo intervention.
Trial: NCT00003714
Drug: Pyrazoloacridine
RxNorm normalized name: Pyrazoloacridine
DrugBank: Pyrazoloacridine (DB12549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV (by vein) over 3 hours every 3 weeks
Trial: NCT04983966
Drug: Desﬂurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5
Trial: NCT04983966
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5
Trial: NCT05918796
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block
Trial: NCT05918796
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone
Trial: NCT04894721
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,6mg/kg of weight orally on days 1 and 7
Trial: NCT04531592
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
Trial: NCT03398252
Drug: Doxazosin XL
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
Trial: NCT00411034
Drug: OROS Hydromorphone HCI
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05651074
Drug: Vicagrel and omeprazole
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets
Trial: NCT05512962
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single suprachoroidal Administration of Triamcinolone acetonide
Trial: NCT05896774
Drug: Maplirpacept
RxNorm normalized name: Maplirpacept
DrugBank: Maplirpacept (DB18441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
Trial: NCT00035971
Drug: raloxifene HCI and alendronate Na
RxNorm normalized name: Alendronate Sodium
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05135871
Drug: Mavacamten
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single fasted oral dose of Mavacamten 15/25 mg on Day 1
Trial: NCT05742789
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
Trial: NCT05742789
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
Trial: NCT05742789
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
Trial: NCT05631405
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients treated with dexamethasone
Trial: NCT05312385
Drug: Isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled isoflurane administered by Sedaconda ACD-S
Trial: NCT05312385
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of propofol
Trial: NCT00297388
Drug: Risperidone, long-acting injectable
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04905550
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.
Trial: NCT01427582
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
Trial: NCT05479136
Drug: PET imaging with 18F fluciclovine
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
Trial: NCT05242029
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 40mg psilocybin in a clinical setting.